Article
Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer.
BMC urology - 25 Feb 2021
Wang Lijuan, Pan Shucheng, Zhu Binbin, Yu Zhenliang, Wang Wei
Abstract excerpt
BACKGROUND: The tumorigenesis of prostate cancer involves genetic mutations. Tumour mutational burden (TMB) is an emerging biomarker for predicting the efficacy of immunotherapy. RESULTS: Single-nucleotide polymorphisms were the most common variant type, and C>T transversion was the most commonly presented type of single-nucleotide variant. The high-TMB group had lower overall survival (OS) than the low-TMB...
Topics
Join the communities discussing this publication.